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any treatment was 23 weeks vs. 9 weeks in pts with BSC, 
p<0.0001. In pts who received local treatment (8: surgery + 
3: RT) median PPS was 51 vs. 21 weeks for CHT, p = 0.36. 
Median PPS for surgery was 51 weeks vs. 17 weeks for RT, p = 
0.62. Pts with poor KPS (<60) at relapse did not benefit from 
local treatment as compared with CHT: median PPS for local 
treatment vs. CHT was 14 vs. 18 weeks, p = 0.81. Median PPS 
for poor KPS pts with BSC was 7 weeks. For the whole group 
of 84 pts, median OS from randomization was 35 weeks: 55 
vs. 30 weeks in pts who received any treatment vs. BSC only, 
p < 0.0001. 
 
 
Conclusions: Our results suggest that an active therapeutic 
approach may be beneficial for selected elderly and/or frail 
pts with rGBM, compared to BSC alone. Re-surgery seems to 
be the most efficacious therapeutic option for rGBM in 
elderly pts with high KPS; in poor KPS pts there is no benefit 
of local treatment (surgery and/or RT) over CHT.  
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Purpose/Objective: To report on outcomes and toxicity after 
proton beam radiotherapy for large non-peripapillary 
choroidal melanoma considered unsuitable for other eye-
sparing therapies in Canada. 
Materials and Methods: We included patients with non-
peripapillary tumors (>2mm from the optic disc) treated with 
proton therapy at TRIUMF, the only ocular proton therapy 
facility in Canada, from 1995-2013. A prospective database 
including patient, tumor, and treatment characteristics was 
updated with ocular complications and follow up status from 
chart reviews. 
Results: In total, 77 patients were included in the analysis. 
The median age was 60 years and the median observation 
time 47 months (0-221 months). More than half of the 
patients (53%) had a tumor located anterior to the equator 
and 35% had involvement of the ciliary body. The median 
tumor diameter was 13.6 mm and the median thickness was 
7.1 mm. The 5 -(10) year actuarial rate was 85 (85)% for 
ocular tumor control, 72 (57)% for metastasis-free survival, 
77 (63)% for overall survival, 22 (22)% for enucleation and 38 
(38)% for complete blindness. 80% of patients with blindness 
had developed neovascular glaucoma. 
For patients with good vision (≥20/50) at baseline, the 5-(10) 
year actuarial rate was 40 (40)% for conservation of vision of 
20/50 or better, 44 (44)% for conservation of vision of 20/200 
or better and 67 (67)% for conservation of vision of counting 
fingers or better.  
On univariate analysis, patients with ciliary body involvement 
had significant worse metastasis-free survival and overall 
survival rates compared to patients without ciliary body 
involvement (p<0.001). 
Conclusions: Proton therapy resulted in acceptable local 
control and survival rates in patients with large anteriorly 
located tumors. The risk of complete blindness and severe 
toxicity requiring enucleation was low and a substantial 
proportion maintained a useful vision.  
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Purpose/Objective: * RECTAL BOOST = RandomizEd 
Controlled Trial for pre-operAtive dose-escaLation BOOST in 
locally advanced rectal cancer. 
Randomized controlled trials (RCTs) are the gold standard to 
evaluate effectiveness of new interventions. RCTs often 
experience difficulties in recruitment and generalizability. 
We introduced the 'cohort multiple Randomized Controlled 
Trial' (cmRCT) to efficiently and simultaneously evaluate 
multiple oncologic of interventions, while maintaining the 
highest level of evidence. 
The RECTAL BOOST* study, which compares response rates 
after boost plus standard chemoradiation (CRT) (intervention 
arm) to standard chemoradiation alone (control arm) in 
patients with locally advanced rectal cancer (LARC), is the 
first clinical study according to cmRCT design. We evaluated 
feasibility of this design in terms of recruitment rates and 
boost-offer acceptance. 
Materials and Methods: The basis of this 'cohort multiple 
Randomized Controlled Trial' (cmRCT) is a cohort consisting 
of all patients with rectal cancer. Patients consent to 
prospective collection of clinical, histological and quality-of-
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life data. In addition, they consent to broad randomization 
for being offered experimental interventions.  
Within this cohort, patients eligible for boost treatment - 
LARC (T3+/4NxM0 or TxN2M0) located ≤10cm from the anus - 
are included in a sub-cohort. From this sub-cohort, a random 
sample is offered the boost treatment in addition to CRT 
(intervention arm); this offer may be accepted or refused. 
Patients who are not randomly selected to be offered the 
boost intervention undergo standard CRT without further 
study notification (control arm). Data will be analyzed 
according to intention-to-treat. 
The boost intervention consists of 5 x 3Gy to the gross tumor 
volume (without concomitant chemotherapy) delivered 1 
week prior to standard CRT (25 x 2Gy combined with 
capecitabine). 
Results: In the past 6 weeks, of the 10 eligible patients, 9 
consented for cohort participation and gave broad consent 
for randomization. All nine patients were randomized. Four 
patients were allocated to the control arm and received CRT 
without further notification. Five patients were allocated to 
the intervention arm and were offered the boost in addition 
to CRT. Three patients accepted and underwent the boost, 
whereas 2 refused because of personal reasons and 
reluctance to undergo MRI. 
Conclusions: The cmRCT design shows potential to achieve 
high recruitment rates (9 out of 10 patients) and offer 
patients interventions by asking broad consent for 
randomization. If the number of patients refusing the offer 
remains high, the boost effect may be diluted, demanding 
advanced statistical solutions (instrumental variable 
analysis). Updated results will be presented in April 2015.  
 
 
Poster: Physics track: Basic dosimetry and phantom 
detector developments/characterisation  
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Purpose/Objective: During the past 10 years, the 
mathematical models proposed for converting an EPID signal 
into absorbed dose to water have evolved considerably by 
integrating correction functions of various degrees of 
complexity to take modern conditions of irradiation into 
account. As a whole, these models require prior knowledge of 
mechanical and dosimetric data for the radiation beams so 
that suitable correction factors can be applied. However, in 
spite of all this sophistication, the results obtained show 
discrepancies between the calculated and measured doses 
that may exceed 5% for image pixels that have received an 
equivalent dose lower than 30cGy in water.  
In this work, we propose a new method for calibrating the 
EPID detector which leads to a simple, robust model of the 
detector response to irradiation by X-ray photons, in 
absorbed dose to water. This modelling applies to all pixels 
of the image, without any correcting factor and whatever the 
level of the equivalent dose in water. 
Materials and Methods: Starting from the hypothesis that the 
grey level (GL) read in each pixel of the image is proportional 
to the average dose in water (D) delivered by the irradiating 
beam for each acquisition frame making up the final image 
(D=Dtot/Nbframes; Dtot: total dose delivered by the beam; 
Nbframes: number of acquisition frames), we established a 
simple relation among all these data:  
D = A + B * ln(GL – C) Equation1 
The coefficients A, B and C are obtained by mathematical 
modelling of the pairs of values of D and GL read on the 
central pixel of a set of images called 'calibration images'.  
Results: Applied to each of the 37 'calibration images', 
Equation 1 showed differences of less than 2% between the 
calculated dose and the dose measured in water for the 
central pixel. When this equation was applied, with no 
additional mathematical correction, to all the pixels of the 2-
D image, the results showed that over 95% of the points of 
the image respected a γ–index criterion fixed at 2%/2mm.  
This modelling was also applied to 2-D EPID images obtained 
by simulating VMAT fields and the results satisfied a γ-index 
criterion fixed at 3%/3mm for more than 95% of the points 
analysed. 
Conclusions: Our method allows the EPID to be considered 
and used as a 2-D detector measuring the absolute absorbed 
dose to water.  
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Purpose/Objective: The complexity of modern radiotherapy 
necessitates comprehensive dose validation which has 
motivated research into three dimensional (3D) dosimetry. 
One such dosimetry system is based on polymerization of 
monomers suspended in a gelatin matrix. To verify the 
performance of such a polymer gel dosimetry system we have 
in this study compared its dosimetric precision to that of 
conventional radiochromic films. 
Materials and Methods: A cylindrical normoxic 
polyacrylamide gel (nPAG) dosimeter (Ø15cm x 15cm) and an 
EBT2 radiochromic film dosimeter (15x15cm2) were irradiated 
with a volumetric modulated arc therapy (VMAT) plan. During 
irradiation the film was embedded in the gel dosimeter to 
obtain similar irradiation conditions. The resulting dose 
distribution consisted of a cylindrical shaped dose region with 
a gradient along the cylinder axis from 5 Gy to 0 Gy. The 
dose distributions were subsequently read out using an 
optical CT scanner and a flatbed scanner, respectively, and 
were then compared to the calculated distribution using a 
voxel-to-voxel difference analysis. 
Results: Good agreement was observed between the two 
measurements and the calculated plan as seen in figure 1. A 
slight deviation of the gel measurement was observed at the 
lowest dose. The voxel-to-voxel difference analysis resulted 
